If patients with mental illnesses are to be treated fairly in comparison with other categories of patients, they must be given access to promising experimental therapies, including psychedelics. The right of early access to promising therapies was advanced as an ethical principle by activist Larry Kramer during the AIDS pandemic, and has now largely been adopted by the medical establishment....
A “pipeline of new psychedelic medicines” to be used in treating addiction is underway, with the most recent announcement from Canada‐based Awakn Life Sciences, which on June 24 named David Nutt its chief research officer. Many of Awakn's candidate medications were acquired in March from Nutt's Equasy Enterprises. Also included in Awakn's list of promising drugs: the only ketamine‐assisted...
Psychedelics have shown great promise in modern clinical trials for treating various psychiatric conditions. As a transdiagnostic treatment that exerts its effects through subjective experiences that leave enduring effects, it is akin to psychotherapy. To date, there has been insufficient discussion of how psychedelic therapy is similar to and different from conventional psychotherapy. In this...
Resume On estime que le syndrome de stress post-traumatique (PTSD) reste chronique et severe pour 25 a 50 % des patients malgre une prise en charge psychotherapeutique. La MDMA (« ecstasy ») possederait des proprietes psychopharmacologiques qui renforcent l’alliance therapeutique et permettent au patient de travailler sur le contenu traumatique sans etre submerge par la peur et l’anxiete. Les...
Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to evaluate the current state of this...
Anorexia Nervosa (AN) is a major health problem with one of the highest mortalities and treatment costs of any psychiatric condition. Cognitive behavioural therapy (CBT) is currently the most widely used treatment for AN in adults but provides remission rates ≤ 50%. Treatment drop-out is exceedingly high and those that persevere with treatment often relapse, causing increased risk of morbidity...
The therapeutic use of psilocybin in psychedelic-assisted therapy models is currently being tested for a variety of indications, necessitating the training of hundreds of therapists. At present, training programs do not include the provision of a psilocybin experience for therapists, and the last time such an experience was offered with a similar compound was through the Spring Grove LSD...
Distributed by Collective Eye Films, 1315 SE 20th Ave. #3, Portland OR 97214; 971-236-2056Produced by Tyler Chandler and Nichaols MeyersDirected by Tyler Chandler2019, Streaming, 84 mins Dosed is a Canadian documentary about a heroin addict named Adrianne. The film follows her through her long-term addictive behaviors, her family background and her attempts to break away from her addiction...
Abstract Introduction Despite the rapid advance of psychedelic science and possible translation of psychedelic therapy into the psychiatric clinic, very little is known about mental health service user attitudes. Objectives To explore mental health service user attitudes to psychedelics and psilocybin therapy. Methods A questionnaire capturing demographics, diagnoses, previous psychedelic and...
Emerging evidence from randomized, double-blind, placebo-controlled clinical trials suggests psychedelic compounds such as 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and lysergic acid diethylamide (LSD), when administered as an adjunct to psychotherapy, that is, psychedelic-assisted psychotherapy (PAP), may be beneficial for treating substance use disorders, posttraumatic stress...